background
aim
present
therapi
chronic
hepat
b
attain
control
limit
proport
small
interf
rna
sirna
offer
new
tool
potenti
therapeut
applic
hepat
b
viru
hbv
given
import
sequenc
ident
effect
sirna
heterogen
hbv
sequenc
among
differ
isol
short
hairpin
rna
shrna
express
plasmid
develop
target
region
conserv
among
major
hbv
genotyp
assess
effect
control
hbv
method
hbv
replicationcompet
plasmid
cotransfect
cell
mice
level
viral
protein
rna
dna
examin
transfect
cell
anim
effect
clinic
isol
genotyp
b
c
also
determin
result
significantli
decreas
level
viral
protein
rna
dna
hbv
genotyp
cell
cultur
mice
compar
suppress
effect
observ
clinic
isol
genotyp
b
c
clone
silent
mutat
target
region
identifi
patient
genotyp
c
mutant
reveal
diminish
sensit
could
select
presenc
cell
cultur
conclus
find
indic
shrna
could
suppress
hbv
express
replic
genotyp
b
c
promis
advanc
treatment
hbv
howev
emerg
resist
mutant
hbv
quasispeci
consid
abbrevi
use
paper
rnai
rna
interfer
shrna
short
hairpin
rna
sirna
small
interf
rna
w
ith
estim
million
chronic
carrier
hepat
b
viru
hbv
infect
remain
one
preval
chronic
viral
infect
human
chronic
infect
caus
seriou
consequ
includ
cirrhosi
hepatocellular
carcinoma
respons
least
million
death
annual
worldwid
thu
control
hbv
infect
prevent
treatment
imper
prevent
vaccin
avail
block
hbv
infect
success
howev
therapeut
intervent
option
chronic
hbv
carrier
delay
prevent
progress
lifethreaten
endstag
liver
diseas
immun
modul
ie
interferon
nucleosid
analogu
ie
lamivudin
approv
mainstream
treatment
chronic
hepat
b
howev
therapi
achiev
limit
respons
none
erad
viru
effect
strategi
includ
antisens
rna
dna
construct
hammerhead
ribozym
domin
neg
hbv
core
protein
still
develop
therefor
quest
potent
antivir
medic
treat
chronic
hepat
b
continu
recent
found
doublestrand
rna
dsrna
trigger
sequencespecif
genesilenc
process
call
rna
interfer
rnai
rnai
specif
potent
mechan
silenc
gene
express
process
doublestrand
rna
nucleotid
nt
short
interf
rna
sirna
plant
serv
hostdefens
mechan
virus
transpos
element
review
waterhous
et
al
discoveri
rnai
pathway
also
exist
mammalian
cell
use
sirna
avoid
cell
death
induc
dsrna
longer
nucleotid
sirna
emerg
novel
therapeut
approach
fight
human
viral
infect
studi
therefor
examin
whether
sirna
inhibit
hbv
replic
express
exhibit
potenti
combat
chronic
hepat
b
cours
work
grow
number
studi
shown
sirna
effect
sever
pathogen
virus
includ
polioviru
hiv
hcv
replicon
influenza
viru
sar
coronaviru
other
sever
studi
employ
sirna
short
hairpin
rna
shrna
inhibit
hbv
also
reveal
rna
interfer
inde
potenti
treat
viral
infect
includ
hbv
howev
variat
sequenc
among
differ
viral
isol
clinic
set
emerg
resist
mutant
constitut
potenti
problem
hinder
efficaci
sirna
work
identifi
target
site
sirna
conserv
among
hbv
genotyp
g
plasmid
express
shrna
target
site
significantli
inhibit
step
hbv
replic
occur
cultur
cell
mice
problem
resist
mutant
also
explor
studi
plasmid
consist
greater
genomelength
hbv
fragment
subtyp
adw
genotyp
initi
hbv
replic
transfect
hepatoma
cell
line
clone
fulllength
hbv
genom
clinic
sampl
method
describ
gunther
et
al
use
amplic
pcr
product
purifi
clone
vector
yt
yeastern
biotech
co
shijr
taiwan
shrna
clone
downstream
human
promot
vector
psuper
describ
target
site
sirna
chosen
basi
conserv
among
major
hbv
genotyp
select
sequenc
submit
blast
search
avoid
target
human
genom
use
primer
rel
posit
shrna
target
hbv
shown
figur
inject
mice
endotoxinfre
plasmid
dna
prepar
endofre
plasmid
kit
qiagen
hilden
germani
cell
grown
co
dulbecco
modifi
eagl
medium
supplement
fc
biolog
industri
kibbutz
beit
haemek
israel
lglutamin
cell
plate
densiti
cell
per
dish
cell
per
well
plate
hour
prior
transfect
transfecion
cell
perform
lipofectamin
invitrogen
life
technolog
ca
follow
user
guidelin
assay
replic
hbv
genom
clinic
isol
cleav
pcr
product
hbv
monom
clone
pyt
sapi
prior
transfect
describ
previous
transfect
supernat
collect
evalu
hepat
b
surfac
antigen
hbsag
hepat
b
e
antigen
hbeag
cell
process
detect
viral
dna
rna
southern
northern
blot
respect
possibl
advers
effect
psuperhbv
cell
evalu
morpholog
growth
rate
nonhbv
protein
express
cytotox
transfect
cell
cytotox
determin
mt
assay
aqueou
solut
prolifer
assay
follow
instruct
manufactur
promega
madison
wi
express
level
one
cellular
protein
determin
tumor
marker
afp
kit
axsym
system
abbott
gmbh
diagnostica
wiesbaden
germani
vivo
experi
use
mice
five
g
g
bd
bioscienc
palo
alto
ca
g
psuper
psuperderiv
plasmid
dna
inject
tail
vein
mice
volum
phosphatebuff
salin
pb
equival
mous
bodi
weight
total
volum
deliv
within
second
secret
alkalin
phosphatas
seap
level
mous
serum
measur
bd
great
escap
seap
chemiluminesc
detect
kit
bd
bioscienc
palo
alto
ca
use
normal
transfect
effici
mice
sera
assay
hbsag
hbeag
hbv
dna
content
day
inject
liver
mice
preserv
optim
cut
temperatur
oct
immunohistochem
analysi
mous
experi
carri
accord
guidelin
establish
institut
anim
care
use
committe
nation
taiwan
univers
colleg
medicin
level
hbsag
hbeag
media
transfect
cell
sera
treat
mice
determin
use
axsym
system
kit
abbott
gmbh
diagnostica
hbv
core
protein
hbc
visual
immunohistochem
stain
tissu
embed
oct
rabbit
antihbc
antibodi
envis
system
hrp
dab
dako
corp
carpinteria
ca
liver
section
also
stain
hematoxylin
total
rna
extract
transfect
cell
rnabe
reagent
teltest
inc
freindswood
accord
manufactur
instruct
twenti
g
rna
separ
electrophoresi
agaros
gel
transfer
nylon
membran
roch
diagnost
gmbh
mannheim
germani
blot
probe
diglabel
dna
fragment
correspond
nucleotid
hbv
x
sequenc
probe
gener
pcr
dig
probe
synthesi
kit
roch
diagnost
gmbh
mannheim
germani
purif
hbv
dna
intracellular
core
particl
perform
accord
protocol
describ
previous
minor
modif
briefli
cell
lyse
l
isoton
lysi
buffer
mmoll
trishcl
mmoll
edta
mmoll
nacl
nonidet
per
dish
nuclei
remov
lysat
centrifug
minut
rpm
cytoplasm
hbv
dna
purifi
digest
protein
gml
proteinas
k
presenc
sodium
dodecyl
sulfat
overnight
phenolchloroform
extract
ethanol
precipit
purif
hbv
dna
extracellular
viral
particl
perform
follow
protocol
describ
previou
studi
one
third
dna
purifi
fraction
agaros
gel
blot
nylon
membran
hybrid
diglabel
dna
fragment
cover
entir
surfac
gene
genotyp
analysi
sirna
target
region
hbv
viral
dna
isol
cellfre
cultur
supernat
qiaamp
viral
rna
kit
qiagen
accord
manufactur
instruct
five
l
purifi
viral
dna
use
templat
pcr
reaction
sens
primer
antisens
primer
pcr
product
purifi
gelpcr
dna
fragment
extract
kit
geneaid
taoyuan
taiwan
sequenc
automat
sequenc
abi
model
primer
analyz
sequenc
individu
clone
pcr
product
clone
vector
pyt
yeastern
biotech
co
examin
abil
sirna
inhibit
hbv
gene
express
target
sequenc
locat
x
surfac
gene
hbv
select
hbv
transcript
overlap
ctermin
multipl
viral
rna
could
inhibit
singl
sirna
figur
sirna
use
target
pregenom
rna
serv
templat
hbv
genom
replic
mrna
core
polymeras
protein
sirna
also
target
transcript
hbv
surfac
antigen
major
viral
protein
envelop
furthermor
target
transcript
encod
x
protein
studi
employ
promoterbas
vector
psuper
express
sirna
interest
form
shrna
evalu
effect
hbv
sirna
hbv
gene
express
measur
hbsag
hbeag
level
cultur
media
cell
cotransfect
replicationcompet
hbv
construct
hbv
shrnaexpress
plasmid
present
studi
found
could
effici
suppress
express
hbsag
hbeag
day
figur
cultur
kinet
effici
suppress
differ
hbsag
hbeag
maxim
suppress
hbeag
occur
around
day
posttransfect
suppress
effect
decreas
thereaft
suppress
psuper
hbsag
express
attain
maximum
level
around
day
maintain
similar
level
thereaft
treatment
caus
approxim
reduct
hbsag
day
hbeag
day
respect
compar
emptyvector
control
figur
convers
show
signific
suppress
effect
hbv
protein
express
data
shown
hbv
rna
level
cell
examin
northern
blot
total
cellular
rna
deriv
transfect
cell
hybrid
probespan
x
gene
hybrid
equal
hbv
transcript
rna
level
kb
kb
kb
significantli
suppress
compar
cell
cotransfect
psuper
vector
alon
figur
consist
result
secret
viral
protein
cultur
supernat
show
suppress
effect
hbv
transcript
rna
level
either
result
indic
suppress
effect
sirna
hbv
express
rna
level
compar
protein
level
thu
use
express
level
viral
antigen
readout
system
viral
rna
express
studi
examin
whether
shrna
could
also
suppress
hbv
replic
use
southern
blot
detect
hbv
dna
shown
figur
also
suppress
hbv
replic
reflect
reduc
hbv
replic
intermedi
transfect
cell
hbv
dna
viral
particl
secret
cultur
media
decreas
hbv
replic
express
cell
due
nonspecif
cell
toxic
morpholog
cell
transfect
differ
markedli
psupertransfect
untransfect
cell
mt
prolifer
assay
psupertransfect
cell
show
compar
prolifer
result
data
shown
furthermor
express
level
cellular
rna
protein
unaffect
presenc
psuper
includ
gapdh
rna
figur
well
secret
afp
express
cell
data
shown
result
indic
decreas
hbv
replic
express
cell
due
nonspecif
cell
toxic
problem
due
specif
suppress
effect
hbv
show
substanti
inhibit
hbv
express
replic
cultur
shrna
express
plasmid
use
examin
whether
could
also
display
hbv
inhibit
vivo
cotransfect
psuper
mous
liver
hydrodynam
inject
level
alkalin
phosphatas
serum
measur
monitor
transfect
effici
hydrodynam
inject
shown
studi
present
author
other
hydrodynam
inject
replicationcompet
hbv
plasmid
dna
mous
result
hbv
replic
liver
secret
viral
antigen
serum
level
hbsag
mous
sera
hbc
express
mous
liver
use
indic
evalu
suppress
effect
concord
find
cell
cultur
experi
hbsag
express
mice
receiv
hbv
replicationcompet
construct
suppress
dramat
serum
hbsag
mice
treat
reduc
day
compar
mice
without
treatment
figur
express
anoth
import
viral
protein
nucleocapsid
hbc
also
inhibit
psuper
hbv
core
protein
synthes
infect
transfect
cell
pregenom
rna
requir
viral
replic
immunohistochem
studi
show
approxim
hbcposit
hepatocyt
liver
mice
receiv
psuper
figur
left
panel
contrast
hbcstain
cell
hardli
found
liver
mice
receiv
figur
right
panel
number
stain
hepatocyt
section
mice
reduc
signific
divers
occur
sequenc
hbv
isol
base
sequenc
diverg
hbv
classifi
least
genotyp
warrant
widespread
applic
potenti
sirna
therapi
target
sequenc
chosen
conserv
among
major
hbv
genotyp
ag
shown
suppress
express
replic
laboratori
clone
genotyp
test
concern
whether
could
also
inhibit
express
replic
hbv
differ
genotyp
clinic
isol
genotyp
b
c
preval
genotyp
asia
includ
taiwan
studi
focus
genotyp
effect
examin
heterogen
mixtur
amplifi
hbv
genom
clinic
sampl
without
clone
fulllength
hbv
genom
genotyp
b
c
amplifi
patient
serum
pcr
pcr
product
digest
sapi
transfect
cell
psuper
psuper
previou
studi
demonstr
linear
monomer
hbv
genom
sapi
end
initi
full
replic
cycl
lead
viral
antigen
express
result
show
could
also
suppress
express
hbsag
hbeag
hbv
genotyp
b
c
clinic
isol
similar
extent
laboratori
clone
genotyp
figur
fulllength
hbv
genom
clinic
isol
also
clone
vector
effect
psuper
express
assay
result
resembl
pcr
product
data
shown
nevertheless
clone
patient
genotyp
c
prove
resist
al
though
total
pcr
product
patient
show
obviou
resist
treatment
sequenc
particular
clone
phbvcim
found
exhibit
silent
mutat
target
sequenc
figur
mutat
chang
amino
acid
sequenc
either
polymeras
gene
surfac
gene
neither
directli
sequenc
pcr
product
clone
patient
display
nucleotid
chang
within
target
sequenc
indic
mutant
clone
repres
minor
popul
next
concern
whether
mutant
clone
would
select
presenc
psuper
mimick
heterogen
popul
hbv
patient
phbvcim
mix
phbvciwt
ratio
transfect
cell
presenc
psuper
hbv
genom
purifi
cultur
supernat
day
posttransfect
hbv
fragment
cover
target
sequenc
amplifi
pcr
product
clone
presenc
proport
hbv
mutant
sequenc
significantli
increas
day
posttransfect
reflect
result
sequenc
pcr
product
directli
least
individu
clone
experi
electropherogram
pcr
product
sequenc
evid
domin
signal
chang
c
sampl
treat
day
posttransfect
day
posttransfect
figur
result
sequenc
individu
clone
also
reveal
increas
mutant
clone
summar
tabl
day
posttransfect
ratio
mutant
clone
quit
similar
sampl
cell
cotransfect
psuper
day
posttransfect
ratio
rose
significantli
sampl
treat
ratio
remain
sampl
treat
vector
psuper
alon
tabl
anoth
independ
experi
ratio
mutant
clone
cell
transfect
psuper
respect
day
posttransfect
result
strongli
impli
sirna
could
exert
select
pressur
preexist
resist
mutant
advantag
highli
specif
potent
safe
gene
silenc
potenti
use
sirna
antivir
agent
activ
explor
numer
studi
work
rna
polymeras
iii
promoterbas
vector
use
express
shrna
hbv
clearli
demonstr
strength
vector
inhibit
hbv
express
replic
cell
cultur
mous
model
system
furthermor
shrnaexpress
plasmid
use
studi
suppress
express
laboratori
prototyp
hbv
strain
also
suppress
express
hbv
clinic
isol
differ
genotyp
prepar
work
sever
studi
document
antihbv
activ
rna
silenc
either
synthet
sirna
shrnaexpress
plasmid
vitro
vivo
result
resembl
present
investig
outcom
support
sirna
promis
approach
control
hbv
make
distinct
target
site
one
conserv
hbv
major
genotyp
g
among
sirna
target
sequenc
publish
far
genotyp
h
contain
nucleotid
differ
within
target
sequenc
nucleotid
nucleotid
previous
identifi
resist
clone
g
genotyp
h
rather
genotyp
nevertheless
genotyp
h
common
worldwid
given
high
heterogen
hbv
sequenc
sensit
sirna
chang
sequenc
advantag
design
potent
sirna
target
highli
conserv
region
among
variou
hbv
isol
howev
challeng
develop
sirna
target
highli
conserv
region
also
effect
hbv
fact
psuper
one
found
far
conserv
sirna
target
sequenc
gener
util
sirna
differ
hbv
genotyp
strain
illustr
suppress
effect
express
hbv
genotyp
b
c
studi
although
inhibitori
effect
genotyp
test
lack
clinic
sampl
like
suppress
express
genotyp
conserv
target
sequenc
although
studi
prove
feasibl
use
sirna
control
hbv
express
replic
vivo
vitro
emerg
resist
mutant
may
problemat
previou
studi
use
sirna
control
replic
human
immunodefici
viru
polioviru
cultur
note
emerg
resist
mutant
resist
mutant
either
emerg
de
novo
molecularli
clone
viral
genom
like
present
initi
viru
popul
select
presenc
sirna
studi
hbv
variant
silent
mutat
within
target
site
found
one
hbv
chronic
carrier
knowledg
first
experiment
proof
resist
mutant
inde
preexist
quasispeci
hbv
patient
data
also
present
support
notion
mutant
select
presenc
sirna
find
togeth
other
underlin
import
sequenc
ident
sirna
target
sequenc
effect
combin
multipl
sirna
target
separ
region
genom
allevi
problem
resist
mutant
use
sirna
target
function
indispens
conserv
region
minim
problem
reduc
number
sirna
use
therefor
cost
mutat
identifi
phbvcim
nucleotid
caus
silent
mutat
surfac
polymeras
gene
within
conserv
target
region
genotyp
h
differ
nucleotid
left
unchang
amino
acid
sequenc
hbv
surfac
protein
caus
leu
val
conserv
chang
polymeras
read
frame
find
impli
probabl
mutat
toler
hbv
within
target
sequenc
therefor
prevent
emerg
resist
clone
simpli
achiev
includ
shrna
mutant
sequenc
problem
may
also
overcom
combin
antivir
strategi
sirna
target
host
factor
dispens
cell
essenti
viru
hbv
transcript
overlap
c
termin
singl
shrna
target
multipl
critic
transcript
simultan
could
design
maxim
inhibitori
potenc
regard
target
hbv
major
transcript
except
x
mrna
interestingli
investig
found
psuper
suppress
express
hbsag
effici
hbeag
although
target
sequenc
transcript
protein
contrast
starget
sirna
use
klein
et
al
result
greater
suppress
hbeag
hbsag
song
et
al
also
notic
sirna
could
vari
suppress
effect
human
immunodefici
viru
differ
cell
type
current
uncertain
sirna
exert
differenti
suppress
effect
target
sequenc
differ
rna
molecul
differ
cell
type
one
possibl
specul
target
sequenc
differ
rna
molecul
may
differ
secondari
structur
bound
differ
protein
thu
make
access
sirna
differ
natur
infect
hbv
use
coval
close
circular
dna
cccdna
templat
transcript
therefor
treat
chronic
hbv
infect
sirna
need
either
sustain
infect
hepatocyt
continu
degrad
hbv
rna
inactiv
cccdna
transcript
thu
far
sirnainduc
gene
silenc
mammalian
cell
seem
transient
like
lack
rna
silencingamplif
mechan
present
worm
plant
recent
develop
lentiviru
retroviru
adenovirusassoci
viru
aav
base
shrna
express
vector
may
provid
promis
approach
longterm
express
mammal
although
safeti
issu
would
concern
effect
sirnashrna
cccdna
hbv
would
easi
address
experiment
system
use
current
studi
neither
hcc
cell
transfect
hbv
dna
mice
hydrodynam
inject
hbv
dna
gener
profici
provid
cccdna
templat
pregenom
rna
synthesi
recent
advanc
induc
dna
methyl
sirna
human
cell
shed
light
use
sirna
inactiv
hbv
cccdna
transcript
studi
address
effect
sirna
hbv
cccdna
studi
clearli
establish
sirnashrna
could
serv
power
potenti
therapeut
tool
treat
hepat
b
infect
well
diseas
although
technic
obstacl
must
overcom
quick
advanc
sirna
technolog
includ
optim
target
sequenc
improv
deliveri
method
express
vector
would
definit
render
sirna
clinic
feasibl
use
futur
furthermor
knowledg
work
mechan
sirnamedi
effect
dna
genom
system
silenc
plant
organ
review
agraw
would
facilit
develop
strategi
induc
activ
mammalian
cell
sirna
becom
even
potent
ideal
therapeut
agent
hbv
well
viral
infect
